Assistive, Neurostim Devices Get 'Patient Preference' Attention From US FDA
Executive Summary
The agency's patient-preference initiative is expanding with a new workshop that will unite FDA lab staff and patients to discuss patient perspectives on assistive and neurological stimulation devices.
You may also be interested in...
FDA Weighs Patients' Risk Tolerance in Approving Obesity Device
The agency approved EnteroMedics’ Maestro neuromodulator to treat obesity despite the device not meeting endpoints in its pivotal trial. The agency relied in part on a survey that found obese patients willing to take more risks in exchange for weight loss.
‘Core Pillars’ Of Safety And Innovation Take Center Stage In FDA Reports
The US FDA has issued a pair of reports focused on device safety and innovation. The reports describe recent steps the agency has taken to improve in the two areas, and what it plans to do next.
Interview: Theradaptive To Enter Clinical Trial For Spinal Fusion Implant
Theradaptive, which makes a device-biologic combination product to help speed bone healing, recently got authorization to start human trials from the US FDA. Medtech Insight spoke to CEO Luis Alvarez about the company’s past, present and future.